All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: New Zealand government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 12, 2020
Details:
The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Pfizer Inc and Germany’s BioNTech, with delivery potentially as early as the first quarter of 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: BioNTech SE
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020
Details:
Rentschler Biopharma will be responsible for key aspects of cGMP drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: German Federal Ministry of Education and Research
Deal Size: $438.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 15, 2020
Details:
BioNTech will use the milestone-based BMBF funding to support its contribution to the Company’s mRNA vaccine program BNT162 that is being co-developed with its partners Pfizer Inc. and Fosun Pharma respectively.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
Details:
German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 2/3 clinical trial in Germany for their BNT162b2 vaccine candidate. The trial evaluates the safety and efficacy of BNT162b2 in up to 30,000 participants between 18 and 85 years of age.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 27, 2020
Details:
Collaboration aims to supply 10 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, to Hong Kong.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162b1
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b1
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
BNT162b1 was administered in a dose that was well tolerated and generated dose-dependent immunogenicity, as measured by RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Phase 1 study will evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval pathway in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: U.S. government
Deal Size: $1,950.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 22, 2020
Details:
BioNTech SE and Pfizer Inc. Announced Agreement with the U.S. Department of Health and Human Services and the Department of Defense to Deliver 100 Million Doses of BNT162, the COVID-19 Vaccine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
Company has decided to continue development with IFX-1 in severe COVID-19 induced pneumonia. The Company plans to initiate a double-blinded, randomized, placebo-controlled Phase III trial that will be adequately powered for statistical analyses.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BC007
Therapeutic Area: Infections and Infectious Diseases Product Name: BC007
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
Berlin Cures Holding AG is evaluating BC 007, a β1-adrenoceptor autoantibody neutralizing ssDNA product, for the treatment of COVID-19. BC 007 consists of a synthetically produced short and unmodified aptamer, which is able to bind to the spike protein of the coronavirus..
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
